Rochester, NY - Researchers are calling for beta-blocker treatment for patients with intermittent claudication, arguing that it is "old school" to avoid them in this high-risk group [1]. The new study ...

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its ...

Cilostazol exhibits its pharmacologic effects via antiplatelet, vasodilatory, and antithrombotic activities. Like pentoxifylline, cilostazol and several of its metabolites exhibit these antiplatelet ...

* Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo Source text for Eikon: Further company coverage: ...

PAD patients with claudication undergoing peripheral vascular interventions (PVIs) in contemporary practice have a 4% risk of amputation within 4 years, with higher risk seen among those ...